Cancer Family
Head and Neck Neoplasm
CI-CAN-00000021Explore in graph →
Non-malignant1,572 active trials17 approved drugs142 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000021Explore in graph →
Clinical trials
6,373 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06982300 | SSTR2 Imaging With [68Ga]Ga-DOTA-TOC PET/CT in NPC(NACASOR) | recruiting | Phase 1 / Phase 2 | 10 | University Medical Center GroningenOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT05044897 | A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC | active not recruiting | Phase 2 | 11 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 |
| clinicaltrials |
| NCT05956587 | A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 121 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT06006169 | A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 186 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05305131 | Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer | recruiting | Phase 2 | 50 | National University Hospital, SingaporeOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | active not recruiting | Phase 2 | 1,609 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 22, 2025 | clinicaltrials |
| NCT05582122 | SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers(SURVEILLE-HPV) | recruiting | Phase 2 | 420 | UNICANCEROTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06509009 | Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT07070479 | Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial | recruiting | Phase 2 | 208 | Ming-Yuan ChenOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT05329532 | Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer(ModiFY) | recruiting | Phase 1 / Phase 2 | 168 | Scancell LtdINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07167329 | Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial(BELIEVE-VHL) | recruiting | Phase 2 | 100 | José Claudio Casali da RochaOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT05758389 | Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors | recruiting | Phase 2 | 29 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT06374602 | Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer | recruiting | Phase 2 | 20 | Saint Petersburg State University, RussiaOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07129772 | Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 53 | The University of Hong KongOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT03070366 | Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC(OMET) | active not recruiting | Phase 2 | 78 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT06989671 | SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC | not yet recruiting | Phase 2 | 430 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Aug 27, 2025 | clinicaltrials |
| NCT06359847 | Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer | recruiting | Phase 2 | 60 | Beijing Scitech-Mq Pharmaceuticals LimitedINDUSTRY | 1 | Aug 24, 2025 | clinicaltrials |
| NCT07138989 | EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 10 | Sun Yat-sen UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT07135804 | Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 45 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Aug 22, 2025 | clinicaltrials |
| NCT07136519 | Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 30 | Affiliated Hospital of Guangdong Medical UniversityOTHER | 0 | Aug 22, 2025 | clinicaltrials |
| NCT07137039 | Neoadjuvant Treatment of Locally Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemotherapy Regimen | not yet recruiting | Phase 2 | 34 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT07137858 | Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advanced Oral Squamous Cell Carcinoma Cardiac, Randomized, Phase II Exploratory Study | not yet recruiting | Phase 2 | 70 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Aug 22, 2025 | clinicaltrials |
| NCT05446467 | Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC | recruiting | Phase 2 | 80 | Zhejiang Provincial People's HospitalOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT06082167 | Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma(STELLAR-305) | active not recruiting | Phase 2 / Phase 3 | 600 | ExelixisINDUSTRY | 26 | Aug 17, 2025 | clinicaltrials |
| NCT05608876 | A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer | active not recruiting | Phase 2 | 15 | QBiotics Group LimitedINDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT06688175 | IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma | enrolling by invitation | Phase 2 | 32 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06970353 | Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer | recruiting | Phase 2 | 40 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07110558 | Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma(PUPA) | not yet recruiting | Phase 2 | 59 | Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07105592 | A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 68 | Fudan UniversityOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT04675333 | Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04) | active not recruiting | Phase 2 | 172 | ALX Oncology Inc.INDUSTRY | 8 | Aug 3, 2025 | clinicaltrials |
| NCT04675294 | Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) | active not recruiting | Phase 2 | 189 | ALX Oncology Inc.INDUSTRY | 9 | Aug 1, 2025 | clinicaltrials |
| NCT06805617 | A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers(I-MAC) | recruiting | Phase 2 | 35 | Glenn J. HannaOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07090707 | PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-006) | not yet recruiting | Phase 2 | 50 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06923826 | Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)(TROP2) | recruiting | Phase 2 | 32 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07085234 | Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC | recruiting | Phase 2 | 30 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07085988 | Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma | recruiting | Phase 2 | 109 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07079410 | Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma(OSCC) | not yet recruiting | Phase 2 | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT06935188 | Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC | recruiting | Phase 2 | 98 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07067268 | Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy | recruiting | Phase 2 | 76 | Fudan UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT05147844 | Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma | recruiting | Phase 2 | 40 | Xinqiao Hospital of ChongqingOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT07055841 | Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 69 | Xiuping DingOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT05286294 | Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders(MITRIC) | active not recruiting | Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT05272696 | Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC | recruiting | Phase 2 | 86 | Guangdong Provincial People's HospitalOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06676722 | SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy | recruiting | Phase 2 | 20 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06811844 | Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC | recruiting | Phase 2 | 208 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors(SPARTA) | recruiting | Phase 2 | 497 | Apollomics Inc.INDUSTRY | 11 | Jun 27, 2025 | clinicaltrials |
| NCT04305795 | An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 23 | Rakuten Medical, Inc.INDUSTRY | 1 | Jun 19, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Oct 3, 2025source: clinicaltrials